Skip to main content

Rare Disease Community On MEDPEDIA Platform

A recent Mayo Clinic-hosted forum on innovation produced the recommendation to apply the "free" or open concept to health care, in forums called "collaborative care networks."  These networks - large databases, really - offer doctors, patients and researchers ways to enter, search and access a vast pool of clinical and anecdotal data unavailable to any one person or institution.

I don't usually reproduce press releases wholesale, but this RareSpace announcement from Medpedia seems to fit this innovative concept;

MEDPEDIA PLATFORM EXPANDS
WITH ADDITION OF RARE DISEASE COMMUNITY
RareSpace Leverages Medpedia’s Technology Platform
SAN FRANCISCO, CA (June 29, 2010) –Medpedia today announces RareSpace, an online knowledge sharing platform designed in partnership with the R.A.R.E. Project and the Children’s Rare Disease Network to advance research and share information about the rare childhood diseases that affect 22.5 million American families. This resource is available now on Medpedia at http://www.medpedia.com/communities/274-RareSpace.
"RareSpace is a unique and valuable tool for families caring for children with rare diseases," says Jonathan Jacoby, CEO of the R.A.R.E Project. "With the help of Medpedia.com, RareSpace will become a safe place to share important information aggregated from the rare disease community at large, which is vital to finding hope for children."

Parents, physicians, medical researchers, patients, advocates and others interested in rare diseases are encouraged to participate in discussions and share information about genetic diseases, innovations in research, standards of care, and best practices in treating rare diseases and disorders. RareSpace also includes translational research and discussions of possible cures for diseases. Medical professionals in RareSpace will answer questions about treatment, best practices, and how to best help these children and their families. Anyone with an interest in rare diseases is invited to join at http://www.medpedia.com/communities/274-RareSpace.

The Medpedia platform, which launched in February 2009, also includes a collaborative online medical encyclopedia, a Professional Network and Directory for health professionals and organizations, and Communities of Interest in which medical professionals and non-professionals can share information about medical conditions and treatments. The Medpedia platform also includes Medpedia Clinical Trials for pushing clinical trial information out to the Web in proper context; Medpedia Answers for asking and answering medical and health questions; Medpedia Alerts for real-time medical and health news alerts; and Medpedia News & Analysis for sharing medical news and commentary.

About the Children’s Rare Disease Network
The Children’s Rare Disease Network (CDRN) is a non-profit advocacy group committed to connecting, educating and empowering the rare disease community, providing a link between families impacted by rare disease.  The CDRN is a division of and developed by the
R.A.R.E. Project which exists to promote rare disease advocacy, research, and accelerated therapy development. For more information, visit www.crdnetwork.org.

About Medpedia
Medpedia is an open platform connecting people and information to advance medicine. Medpedia is created in association with Harvard Medical School, the Stanford School of Medicine, The University of Michigan Medical School, the UC Berkeley School of Public Health, and leading health organizations around the world. For more information, visit Medpedia.com.

Comments

Popular posts from this blog

Michael Porter On Health Care Reform

Michael Porter, writing in the New England Journal of Medicine, proposes "A Strategy For Health Care Reform - Toward A Value-Based System." His proposals are fundamental, lucid and right-on, meaning they're sure to be opposed by some parties to the debate, the so-called "Yes, but..." crowd. Most important, in my opinion, is this: "... electronic medical records will enable value improvement, but only if they support integrated care and outcome measurement. Simply automating current delivery practices will be a hugely expensive exercise in futility. Among our highest near-term priorities is to finalize and then continuously update health information technology (HIT) standards that include precise data definitions (for diagnoses and treatments, for example), an architecture for aggregating data for each patient over time and across providers, and protocols for seamless communication among systems. "Finally, consumers must become much mor

Being Disrupted Ain't Fun. Deal With It.

Articles about disrupting healthcare, particularly those analogizing, say, Tesla's example with healthcare's current state, are frequently met with a chorus of (paraphrasing here) "Irrelevant! Cars are easy, healthcare is hard." You know, patients and doctors as examples of "information asymmetry" and all that. Well, let me ask you this: assuming you drive a car with a traditional internal combustion engine, how much do you know about the metallurgy in your car's engine block? I'll bet the answer is: virtually nothing. In fact it's probably less than you know about your own body's GI tract. Yet somehow, every day, us (allegedly) ignorant people buy and drive cars without help from a cadre of experts. Most of us do so and live happily ever after (at least until the warranty expires. Warranties...another thing healthcare could learn from Tesla.) Now, us free range dummies - impatient with information asymmetry - are storming healthcare

My Take On Anthem-Cigna, Big Dumb Companies and the Executives Who Run Them

After last Friday's Appeals Court decision, Anthem's hostile takeover of, er, merger with Cigna has but a faint pulse. Good. Unplug the respirator. Cigna's figured it out but Anthem is like that late-late horror show where the corpse refuses to die. Meanwhile, 150 McKinsey consultants are on standby for post-merger "integration" support. I guess "no deal, no paycheck..." is powerfully motivating to keep the patient alive a while longer. In court, Anthem argued that assembling a $54 billion behemoth is a necessary precondition to sparking all manner of wondrous innovations and delivering $2.4 billion in efficiencies. The basic argument appears to be "We need to double in size to grow a brain. And just imagine all those savings translating directly into lower premiums for employers and consumers."  Stop. Read that paragraph again. Ignore the dubious "lower premiums" argument and focus on the deal's savings. $2.4 billion saved